XCR1 and neoplasm: When Xcr1-Cre was used to delete either MHC-II or CD40, tumor rejection was severely reduced, which suggests that a cognate interaction between CD4 T cells and cDC1s is required, at least to realize the full effect of CD8 T cell priming.